Endogenous Trapped Insulin Syndrome (ETIS): A Novel Hypothesis of Intracellular Insulin Sequestration, Therapeutic Window Exploitation, and Prevention of Insulin Dependency in Type 2 Diabetes Mellitus

Read full text Summarise with VIRAT
Authors: Aditya Mishra
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder defined by the dual pathology of peripheral insulin resistance and beta cell dysfunction. While insulin resistance has been extensively studied and therapeutically targeted, the intracellular fate of insulin synthesized by failing beta cells has received comparatively little attention as a distinct therapeutic domain. Current clinical paradigm dictates that progressive oral hypoglycemic agent (OHA) failure inevitably leads to exogenous insulin initiation — a transition widely accepted as a natural consequence of beta cell exhaustion. However, a critical and previously unrecognized pathophysiological question remains unanswered: what happens to the insulin that is synthesized, processed, and stored within secretory granules of beta cells that have lost their capacity for exocytosis? Hypothesis We propose *Endogenous Trapped Insulin Syndrome (ETIS)* — a novel pathophysiological construct describing the intracellular sequestration of biologically viable insulin within secretory granules of failing beta cells in T2DM. Despite progressive exocytosis failure, beta cells continue synthesizing and storing insulin in mature secretory granules where it remains biochemically intact, structurally competent, and potentially releasable for a finite *therapeutic window of approximately 3–5 days*. Beyond this window, trapped insulin undergoes irreversible intracellular degradation through crinophagy, macroautophagy, oxidative modification, glycation, and IAPP oligomer-mediated granule destruction — resulting in permanent depletion of the endogenous insulin reserve and accelerating the trajectory toward exogenous insulin dependency. Proposed Mechanism ETIS develops through four sequential stages: *Stage 1 (Pre-ETIS)* — compensated exocytosis failure with intact insulin synthesis and maximal therapeutic opportunity; *Stage 2 (Evolving ETIS)* — progressive granule accumulation with accelerating intracellular degradation and partial therapeutic window; *Stage 3 (Established ETIS)* — irreversible depletion of viable insulin reserve with minimal intervention benefit; and *Stage 4 (Post-ETIS)* — absolute exogenous insulin dependency with complete loss of endogenous reserve. The bioactive window of trapped insulin is critically shortened in T2DM by glucotoxicity, lipotoxicity, zinc transporter 8 (ZnT8) dysfunction, islet amyloid polypeptide (IAPP) oligomer formation, lysosomal membrane permeabilization, and oxidative stress — collectively accelerating intracellular insulin degradation beyond the physiological rate observed in healthy beta cells. Therapeutic Proposition Pharmacological exploitation of the ETIS therapeutic window through a rationally designed, multi-target intervention regimen can release viable trapped insulin, restore glycemic control, reduce beta cell synthetic burden, interrupt the ETIS vicious cycle, and prevent progression to exogenous insulin dependency. The proposed *ETIS Prevention Protocol* comprises: *Repaglinide* as the primary meal-linked exocytosis trigger; *Metformin* for glucotoxicity reduction and mitochondrial support; *DPP-4 inhibitors* for cAMP-mediated signal amplification and granule pool mobilization; *Pioglitazone* for beta cell preservation and lipotoxicity reduction; and *Zinc supplementation with antioxidants* (Alpha-lipoic acid, N-Acetylcysteine) for granule stabilization and extension of the bioactive window. This protocol is designed to maximize the exploitation of endogenous insulin reserves during the therapeutic window — achieving glycemic control through the patient's own insulin rather than exogenous replacement. Relationship to Insulin Trap Syndrome (ITS) ETIS is proposed as the mechanistic *precursor phase* of the previously described *Insulin Trap Syndrome (ITS)* — a published hypothesis describing conditioned anticipatory counter-regulatory response, triple organ gluconeogenic storm, and iatrogenic insulin dependency in T2DM. Together, ETIS and ITS constitute a *Dual-Phase Insulin Trapping Continuum*: ETIS depletes the endogenous insulin reserve, making exogenous insulin appear necessary; ITS is then triggered by the initiation of exogenous insulin, establishing iatrogenic dependency. Prevention of ETIS through therapeutic window exploitation therefore prevents not only endogenous insulin depletion but also the downstream development of ITS — offering a unified strategy to fundamentally alter the natural history of T2DM. Conclusion ETIS represents a previously unrecognized, biologically grounded, and potentially preventable pathophysiological stage in T2DM progression. The identification of a finite therapeutic window of viable trapped insulin, and the rational pharmacological strategy to exploit it, offers a paradigm shift in T2DM management — from reactive exogenous insulin replacement to proactive endogenous insulin preservation. This hypothesis warrants urgent validation through clinical biomarker studies, human islet research, and randomized controlled trials targeting the ETIS therapeutic window. Keywords Endogenous Trapped Insulin Syndrome, ETIS, Type 2 Diabetes Mellitus, Beta cell exocytosis failure, Insulin secretory granules, Crinophagy, Therapeutic window, Intracellular insulin sequestration, Repaglinide, DPP-4 inhibitors, Zinc transporter 8, ZnT8, IAPP , Insulin dependency prevention, Insulin Trap Syndrome, ITS, Dual-phase insulin trapping, Beta cell preservation, Glucotoxicity, Lipotoxicity, Proinsulin, C-peptide, HOMA-B, Oral hypoglycemic agents, Iatrogenic insulin dependency

Fields of Study & Subjects

Pancreatic function and diabetes Diabetes Treatment and Management Diabetes and associated disorders

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
21 March 2026
Language
EN